Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers

Acta Pharmaceutica Sinica B

Liang Ouyang¹  Yi Chen²  Tingting Jiang³  Yao Liu³  Jie Liu³  Guan Wang³  Meng Wang³  Lu Feng³ 

[1] Corresponding authors. Tel./fax: [phone].;State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China;State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China;

关键词: Tropomyosin receptor kinase;    Neurotrophic receptor tyrosine kinase fusions;    Small-molecule inhibitor;    NTRK fusion cancer;   

DOI  :  

来源: DOAJ

【 摘 要 】

Tropomyosin receptor kinase A, B and C (TRKA, TRKB and TRKC), which are well-known members of the cell surface receptor tyrosine kinase (RTK) family, are encoded by the neurotrophic receptor tyrosine kinase 1, 2 and 3 (NTRK1, NTRK2 and NTRK3) genes, respectively. TRKs can regulate cell proliferation, differentiation and even apoptosis through the RAS/MAPKs, PI3K/AKT and PLCγ pathways. Gene fusions involving NTRK act as oncogenic drivers of a broad diversity of adult and pediatric tumors, and TRKs have become promising antitumor targets. Therefore, achieving a comprehensive understanding of TRKs and relevant TRK inhibitors should be urgently pursued for the further development of novel TRK inhibitors for potential clinical applications. This review focuses on summarizing the biological functions of TRKs and NTRK fusion proteins, the development of small-molecule TRK inhibitors with different chemotypes and their activity and selectivity, and the potential therapeutic applications of these inhibitors for future cancer drug discovery efforts.

【 授权许可】

Unknown